Radium-223 is a radiopharmaceutical localizing to bone and is approved for treatment of bone metastases in prostate cancer. Safety and efficacy data regarding hematologic events from radium-223 therapy are discussed.
Introduction
Prostate cancer is the most common cancer in men in the United States.
1,2 Metastatic castration-resistant prostate cancer (CRPC)
represents end-stage disease affecting approximately 40,000 men in the United States. 3 The 5-year overall survival (OS) for men with metastatic CRPC (mCRPC) is 29%. 4 Most (w 90%) patients with mCRPC develop bone metastases, 5 a significant cause of morbidity and mortality. 6 Since 2010, the armamentarium of drugs to treat CRPC has expanded. Androgen pathway inhibitors abiraterone and enzalutamide, chemotherapy agent cabazitaxel, and sipuleucel-T immunotherapy have improved survival and are often provided sequentially. Radium-223 dichloride (Ra-223) is a bone-seeking targeted alpha (a)-emitting radiopharmaceutical also recently approved for the treatment of symptomatic bone metastases. Whereas the b-emitting radiopharmaceuticals strontium-89 and samarium-153 are used for pain palliation of bone metastases, treatment with Ra-223 provides a survival advantage in patients with mCRPC. 7 Ra-223 has advantages over external beam radiotherapy (EBRT), analgesics, and osteoclast inhibitors for mitigating skeleton-related events. EBRT is suited only for well-defined bone metastases, and extended field radiation is often accompanied by significant adverse events (AEs). Osteoclast inhibitors do not affect survival but instead slow or reverse progression of bone metastases and improve bone mineral density. therapies on bone marrow is unknown. A confounding factor is that myelosuppression often occurs in mCRPC related to infiltrative bone disease. 10 Questions remain regarding appropriate sequencing of available agents to maximize therapeutic benefit while preserving bone marrow reserve for future treatment. Data are needed on optimally integrating Ra-223 therapy into existing treatment options for men with mCRPC. The goals of this review were to summarize safety and efficacy results from clinical trials and institutional safety data pertaining to hematologic AEs occurring with Ra-223, and to discuss practical management issues.
Mechanism of Action of Ra-223
Ra-223 is an a-emitting radionuclide that localizes to bone matrix by binding to bone mineral hydroxyapatite. 11 Ra-223 decay events result in high linear energy transfer delivery to the surrounding environment, leading to a high frequency of doublestranded DNA breaks in adjacent tumor cells and subsequently to cancer cell death. The a-particle range of Ra-223 is < 100 mm, thereby theoretically maximizing dose to cortical bone and metastatic cells while minimizing dose to the marrow and other normal tissues. Ra-223 has a rapid decay cascade, which limits the diffusion of radioactive daughter nuclides. 7, 11 These properties of Ra-223 aparticles are advantageous because the frequency of lethal doublestranded DNA breaks to tumor cells is higher, with less hematologic toxicity, compared to b particles of samarium-153 and strontium-89.
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Efficacy and Nonhematologic Toxicity of Ra-223
The phase 3 randomized, double-blind, placebo-controlled ALSYMPCA clinical trial with Ra-223 (NCT00699751; n ¼ 921) in patients with CRPC and symptomatic bone metastases demonstrated a 30% reduction in the risk for death versus standard of care 7, 13 and a significant improvement in OS (median, þ3.6 months), regardless of previous docetaxel use. 7, 13, 14 The time to first skeleton-related event was significantly longer with Ra-223 compared to the standard of care (median, 15.6 vs. 9.8 months, respectively; P ¼ .00037), 7, 13 and the Eastern Cooperative Oncology
Group performance scores improved in the Ra-223 group.
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Recent analysis of European Quality of Life-5 Dimensions (EQ-5D) questionnaire and Functional Assessment of Cancer Therapy-Prostate (FACT-P) data from the ALSYMPCA trial demonstrated a slower decline of quality of life over time and a meaningful improvement in EQ-5D utility and FACT-P total score in the Ra-223 group versus the standard-of-care group. 15, 16 The efficacy of Ra-223 was evaluated in expanded-access programs. 17, 18 In the first expanded-access program, patients (n ¼ 184) with fewer previous treatments completed more cycles of Ra-223 than did patients who received more previous treatments.
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In the second expanded-access program (n ¼ 696), OS was higher in patients who received concomitant denosumab or abiraterone, and longer OS was observed in patients with good Eastern Cooperative Oncology Group performance scores, no pain, and low alkaline phosphatase (ALP) levels. 18 Ra-223 was well tolerated in ALSYMPCA. Nonhematologic grade 3/4 AEs (incidence ! 5%) were not significantly different between the Ra-223 and placebo groups and included fatigue (5% vs. 6%), bone pain (21% vs. 26%), and spinal cord compression (3% vs. 6%), respectively. 7 In a post hoc analysis, treatment discontinuation due to AEs was similar in patients receiving Ra-223 compared to patients receiving placebo, indicating a positive Ra-223 treatment effect and safety profile (Table 1) . 19 Overall, 65%
(391/600) of patients in the Ra-223 group and 48% (144/301) of patients in the placebo group received all of the recommended 6 injections. The most common AE leading to treatment discontinuation was disease progression (Table 1) . 19 Hematologic Safety of Ra-223
Overall rates of hematologic AEs in ALSYMPCA were low in the Ra-223 group and were similar to placebo (Table 2) . 20, 21 There were no significant differences between Ra-223 and placebo for all grades of anemia (31% vs. 31%, respectively) or grade 3/4 anemia (13% vs. 13%, respectively). Grade 3/4 neutropenia rates were not significantly different between the Ra-223 and placebo groups (2% vs. 1%, respectively), although more neutropenia was observed with Ra-223 compared to placebo for all grades (5% vs. 1%, respectively; P ¼ .005). Grade 3 febrile neutropenia occurred in 1 (< 1%) of 600 patients who received Ra-223 and in 1 (< 1%) of 301 patients who received placebo. 19 The rates of thrombocytopenia were significantly higher in the Ra-223 group than in the placebo group for all grades (12% vs. 6%, respectively; P ¼ .002) and for grade 3/4 (6% vs. 3%, respectively). One patient in the Ra-223 group had grade 5 bone marrow failure related to the study drug.
20
Of the 901 patients in the ALSYMPCA safety population, 571 entered the 3-year follow-up period, wherein the incidence of hematologic AEs was low (Table 2) . 20, 21 There were no reports of acute myelogenous leukemia, myelodysplastic syndrome, or new primary bone cancers at the end of this period (Table 2 ). Moreover, there were no significant associations between hematologic toxicities and the number of received Ra-223 injections. 20 A post hoc analysis evaluating hematologic parameters throughout follow-up in ALSYMPCA generally showed a low incidence of myelosuppression over time. 20 Hemoglobin levels declined in both the Ra-223 and placebo groups, with significantly mildly lower hemoglobin levels in the Ra-223 group versus the placebo group in the early follow-up period (weeks 44, 51, and 69; Figure 1 ). 19 For patients receiving Ra-223, the median absolute neutrophil counts (ANCs) decreased modestly over time, with some recovery during follow-up, but ANC did not significantly change from baseline for patients receiving placebo. In both groups, platelet counts decreased over the treatment period, with larger reductions in patients who received Ra-223 than in patients who received placebo, but counts remained relatively constant in the follow-up period.
20,21
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Effects on the Immune System. Data on immune response changes following Ra-223 are limited. In a recent study of 11 patients with mCRPC, immune function was determined by lymphocyte proliferation and production of interferon-g and interleukin-10. These immune parameters were assessed before and after Ra-223 administration at days 1, 7, and 28. Lymphocyte proliferation and interferon-g and interleukin-10 production remained unchanged throughout the 28-day period. Within the follow-up period, no changes to mitogen or microbial challenges were observed; nor were infectious complications reported. The authors concluded that immune responses against pathogens should remain unaffected by Ra-223. 22 One limitation of this study was whether immune responses were tested after a single or multiple doses of Ra-223. Furthermore, in a preliminary study of 7 patients with mCRPC who received Ra-223, levels of programmed cell death 1 expression decreased on effector memory CD8 þ T cells and memory CD4 þ T cells after Ra-223. Further investigation concerning the role of immune responses after Ra-223 may be warranted.
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Association With Secondary Malignancies. Leukemia associated with Ra-223 in clinical trials was not reported; however, 2 recent case studies reported leukemia in patients who received 5 to 6 lines of treatment including Ra-223. 24, 25 The first was a 69-year-old patient with mCRPC who developed acute myeloid leukemia 9 months after treatment with Ra-223. 25 In the second, a patient with mCRPC received hormone therapy and Ra-223, followed by docetaxel approximately 1 year later. Progressive pancytopenia developed after completing docetaxel, 18 months after completing Ra-223. Histology from bone marrow biopsy demonstrated acute promyelocytic leukemia. 24 At present, there is insufficient evidence to conclude a causal link between Ra-223 and the development of any secondary malignancy. In both cases above, the patients received numerous lines of therapy, complicating attribution of hematologic malignancies to Ra-223 as a single causative factor. Moreover, although prostate cancer cells share the same niche in bone microenvironment as hematopoietic stem cells, 26 no data confirm that hematopoietic stem cells and a particles of Ra-223 interact. Regardless, secondary malignancies have been associated with EBRT and chemotherapy. 27 The case reports highlight increased vigilance in monitoring these patients for secondary malignancies, particularly given the relatively short follow-up of 3 years for clinical trial data.
Effect of Previous Treatment on Hematologic AEs From Ra-223. Retrospective studies evaluating Ra-223 in clinical practice have shown mild hematologic toxicities in patients receiving Ra-223 after chemotherapy, consistent with Ra-223 clinical trials. In a retrospective, singleinstitution study of 110 patients with mCRPC who received Ra-223, there was no significant increased risk for bone marrow failure in patients who received chemotherapy before Ra-223. 28 The association of hematologic toxicity of Ra-223 and previous treatments was assessed in a recent retrospective study of heavily pretreated patients with mCRPC (n ¼ 145) who received ! 1 doses of Ra-223 (Table 3) . 29 Overall, anemia and thrombocytopenia were more common than neutropenia, but were predominantly grade 1 or 2. Grade 3/4 hematologic toxicity occurred in 5% of patients for anemia, 3% for neutropenia, and 5% for thrombocytopenia. Hematologic toxicity in this cohort was similar regardless of type (or combination) of previous treatment (chemotherapy alone vs. enzalutamide or abiraterone vs. chemotherapy and abiraterone and enzalutamide). Abiraterone and enzalutamide were approved after patient accrual closed for the ALSYMPCA clinical trial. In this study, 20% of patients received antiandrogen therapy concurrent with Ra-223, but hematologic toxicity data are not reported separately for concurrent versus previous use.
Another study showed decreased likelihood of completing all doses of Ra-223 with previous use of enzalutamide and abiraterone, which was hypothesized to be due to patients receiving Ra-223 later in their disease course. Patients with a history of chemotherapy use were not less likely to finish treatment. 30 Hematologic Toxicity With Combination Treatment With Ra-223. Safety and OS of 696 patients treated with Ra-223 and receiving concomitant therapies were assessed in an open-label, early-access, single-arm mCRPC study conducted after ALSYMPCA and before the approval of Ra-223 by the US Food and Drug Administration. 18 Patients with histologically or cytologically confirmed, progressive, bone-predominant mCRPC with ! 2 skeletal metastases on imaging; those who were symptomatic or asymptomatic; and those with lymph node but not visceral disease were allowed to participate in the clinical trial. The median OS was longer in patients who received concomitant abiraterone, enzalutamide, or both and in patients who received Ra-223 plus denosumab. The most common grade 3 or higher AEs were anemia (n ¼ 32 patients; 5%), thrombocytopenia (n ¼ 15; 2%), neutropenia (n ¼ 10; 1%), and leukopenia (n ¼ 9; 1%); these rates were consistent with those in the ALSYMPCA clinical trial. 18 Other studies also confirmed that combining Ra-223 with androgen receptor pathway blockers did not increase hematologic toxicity. 31 In an ongoing study (conducted in 2 US centers) of Overall, the incidence of hematologic toxicities appears consistent with or without concomitant treatments that include enzalutamide and abiraterone. Concurrent use of abiraterone, but not enzalutamide, has been associated with the increased likelihood of completing 5 to 6 doses of Ra-223, 30 as well as improved OS, progression-free survival, and bone event-free survival. 28 Concomitant EBRT did not adversely affect Ra-223 hematologic safety in ALSYMPCA. 33 However, in a large single-institution study, EBRT concurrent with or after Ra-223 therapy, but not before, was an independent predictor of bone marrow failure. 28 Hematologic AEs in Elderly Patients. Prognosis is of concern with all patients but is particularly relevant to the elderly, in whom expected benefits and toxicity must be balanced considering concomitant disease and competing potential causes of death. Notable is age-related alterations in pharmacokinetic or pharmacodynamic profiles, resulting in reduced efficacy or increased toxicity. This is at most a minor concern for patients receiving Ra-223 because it is a radiopharmaceutical that decays over time and is excreted, predominantly in feces. 34 The efficacy and safety of Ra-223 were assessed in a retrospective study of elderly patients with mCRPC (n ¼ 129) who were treated at 2 centers. Patients were stratified by age (< 72 and ! 72 years) and received a median of 5 cycles of Ra-223 (50 kBq/kg). 35 There were no significant differences in clinical benefit between patients aged < 72 years versus aged ! 72 years; minimal toxicities were reported. Patients aged < 72 years had higher rates of hematologic toxicities than those aged ! 72 years, including 11 of 13 patients who had grade 3 anemia (P < .009). There was a higher rate of prior docetaxel use in the group aged < 72 years, which could be one factor contributing to this finding. However, drawing such conclusions is difficult because other details regarding the reasons why this group received more chemotherapy or other factors are not provided that could have influenced the development of hematologic toxicity, such as volume of bone metastases or prior radiation. One patient in each group had grade 3 neutropenia; neutropenic sepsis or grade 3 thrombocytopenia were not observed. Eleven patients (9%) developed skeleton-related events during treatment. 35 
Retreatment With Ra-223
Retreatment with Ra-223 was assessed in a subanalysis of ALSYMPCA in patients (n ¼ 44) with CRPC having ! 2 bone metastases who completed 6 initial Ra-223 injections, with no progression of bone disease during treatment. 36 Patients also received ! 2 hormone regimens (73% had disease that failed to respond to this therapy), and 45% had ! 1 lines of chemotherapy. The median time from end of initial Ra-223 treatment and retreatment was 6 months. No new safety signals emerged, and AEs were comparable to or lower than in ALSYMPCA. Only 2 patients had grade 3 hematologic AEs, and only 1 patient had radiographic bone progression. Median progression-free survival was 9.9 months. Disease progression was controlled, with minimal hematologic toxicity. 36 
Other Considerations Regarding Hematologic AEs Associated With Ra-223
Optimal integration of therapeutic agents into clinical practice after regulatory approval is challenging. Predicting hematologic toxicity from baseline risk factors has been of interest because hematologic AEs are one reason for early discontinuation, which has important implications for future treatment options, quality of life, and OS. The OS advantage has been associated with receiving 4 to 6 doses of Ra-223. 7, 29 Immediately after Ra-223 approval, clinical trial data were revisited and clinical experiences with Ra-223 were evaluated to help inform the general oncology community about optimal patient selection. Results of multivariate analyses evaluating baseline risk factors for predicting hematologic toxicities with Ra-223 are shown in Table 4 . 20 Baseline characteristics of patients in the Ra-223 safety arm significantly associated with the development of grade 2 to 4 anemia were the extent of disease (6-20 vs. < 6 metastases; odds ratio [OR], 2.76; P ¼ .022), higher PSA levels (log baseline PSA per 10-fold increase; OR, 1.65; P ¼ .006), higher total ALP levels (log baseline total ALP per 10-fold increase OR, 2.00; 
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P ¼ .019), and lower baseline hemoglobin levels (per 1-unit decrease; OR, 1.84; P < .001). 20 The risk for grade 2 to 4 neutropenia increased with previous docetaxel therapy (OR, 3.44; P ¼ .020), the World Health Organization ladder cancer pain score (2 vs. 3; OR, 3.58; P ¼ .042), and reductions in baseline neutrophil counts (per 1-unit decrease; OR, 2.01; P < .001). 20 Significantly increased risk for grade 2 to 4 thrombocytopenia was associated with previous docetaxel therapy (yes/no; OR, 2.16; P ¼ .035) and decreases in baseline hemoglobin levels (per 1-unit decrease; OR, 1.35; P ¼ .008) or platelets (per 100-unit decrease; OR, 1.44; P ¼ .030). No significant association existed among patients who received 4 to 6 cycles of Ra-223 versus patients who received 1 to 3 cycles of Ra-223 (OR, 1.14; P ¼ .837). 20 Another post hoc multivariate analysis of hematologic AEs from the ALSYMPCA clinical trial indicated that grade 3/4 neutropenia was higher for those provided Ra-223 with previous docetaxel use versus no previous docetaxel use. Thrombocytopenia was higher with Ra-223, previous docetaxel use, greater extent of disease (> 20 metastases), and prior bisphosphonate use. 37 In ALSYMPCA and the post hoc analyses of hematologic AEs, patients were categorized as "yes" or "no" for prior use of docetaxel, and further stratification by number of prior cycles was not reported to specify after how many cycles of docetaxel the risk of hematologic AEs is increased. In a retrospective single-institution study, 110 patients with mCRPC, approximately 50% of whom were considered to have a high burden of skeletal disease, received Ra-223. The primary end point was OS from the initial Ra-223 dose until date of death from any cause or last follow-up. 30 Secondary end points were progression-free survival, bone event-free survival, time to progression, and bone marrow failure. Independent variables associated with bone marrow failure in multivariate analyses included the total number of Ra-223 cycles (hazard ratio [HR], 0.75; 95% CI, 0.57-0.97; P ¼ .027) and EBRT during or after Ra-223 therapy (HR, 4.38; 95% CI, 1.37-14.03; P ¼ .013). One hypothesis for the observed protective effect of number of Ra-223 cycles against bone marrow failure was that Ra-223 treated the infiltrative bone disease. There was a benefit for patients who completed the full 6-cycle course of Ra-223 treatment (53%), even for those with apparent progressive disease, including reduced risk for death (À44%), disease progression (À33%), skeleton-specific event (À38%), or bone marrow failure (À30%), compared to those who did not receive all 6 doses. 30 Patients who completed 6 cycles of Ra-223 also demonstrated that skeletal burden on baseline 18 F-fluoride positron emission tomography/computed tomography (PET/CT) predicted bone marrow failure after treatment. Grade 3/4 bone marrow toxicity occurred in 16 (39%) of 41 patients. In this multivariate analysis, the only independent predictor of bone marrow failure was total lesion fluoride index ! 12,000 (HR, 6.66; P ¼ .0237). 28 The authors concluded that 18 F-flouride PET/CT could identify patients at risk for bone marrow failure during Ra-223 treatment, perhaps leading to increased surveillance and early intervention if blood counts decrease. 28 McKay et al 30 evaluated 135 patients with mCRPC to determine baseline variables associated with the completion of all 6 doses of Ra-223. Although not a direct study of hematologic toxicity from Ra-223, the study relates to reasons for discontinuation of therapy, and the total doses of Ra-223 received may reduce the risk for bone marrow failure. In this study, 7 patients discontinued Ra-223 early for toxicity, and the independent predictors of therapy completion in a multivariable analysis included previous treatment with sipuleucel-T (P ¼ .009), hemoglobin, and ANC greater than the lower limit of normal (P ¼ .037 and P ¼ .029, respectively).
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A recent study suggested that baseline bone scan index is a promising prognostic biomarker for hematologic toxicity and OS after Ra-223 therapy. However, the study included a small cohort (88 patients) with advanced mCRPC. Further validation of bone scan index in earlier-stage disease and larger patient numbers are needed before decisions about treatment can be made on the basis of bone scan index. 38 A hematologic evaluation should be performed before initiating Ra-223, and the required baseline parameters should include ANC ! 1.5 Â 10 9 /L, platelet count ! 100 Â 10 9 /L, and hemoglobin levels ! 10 g/dL (Table 5) . 31, 39 Although no prediction model is failsafe, the baseline hematologic parameters along with the other risk factors for hematologic toxicity discussed above can be used as guidance for the provider in discussion of risk with the patient. To monitor for possible myelosuppression during treatment, hematologic parameters (particularly hemoglobin, ANC, and platelet count) should be assessed before each intended cycle of Ra-223 (Table 5) . 39 In general, blood counts may fluctuate during therapy; however, if values diminish to ANC < 1.0 Â 10 9 /L or platelet counts to < 50 Â 10 9 /L and do not recover within 6 to 8 weeks despite supportive care, Ra-223 should be discontinued. Other AEs are generally transient and reversible because bone is quickly targeted with little or no redistribution from decay sites, virtually no urinary excretion, and slow gastrointestinal clearance. 39 In addition to monitoring blood counts, fluid status should be monitored, especially in patients with gastrointestinal AEs (eg, diarrhea, constipation, nausea, and vomiting). In ALSYMPCA, blood transfusions were not allowed within 4 weeks of randomization. 7 There are few data on transfusion use during Ra-223 treatment. In the post hoc hematologic safety analysis, the proportion of patients undergoing transfusions was similar between Ra-223 (42%) and placebo groups (39%). 20 In a retrospective study of postclinical trial experience with Ra-223, 27 (20.1%) of 135 patients required supportive care. 30 In addition to single laboratory evaluations before each subsequent administration of Ra-223, evaluation of trends of hematologic parameters and rates of development of cytopenias can be helpful when considering delaying or discontinuing therapy. Distinction between hematologic toxicity from Ra-223, disease progression, or a combination may not always be possible. In our clinical experience, a multidisciplinary team approach has helped optimize patient selection and follow-up for patients receiving Ra-223.
Practical Considerations
Although there are no definitive guidelines regarding sequencing of agents in mCRPC, we believe that the emphasis with Ra-223 should be on the OS benefit, and it should be emphasized that this is an antitumor drug, not an agent utilized for pain palliation. With that knowledge, introduction of Ra-223 at the earliest possible symptomatic time point is logical, as it likely avoids potential challenges with hematologic toxicity. Patients with fewer bone metastases, lower anaplastic lymphoma kinase, and no previous chemotherapy or radiation to bone are likely to have well-preserved hematologic parameters and experience less toxicity. Additionally, patients with more advanced disease may be less likely to complete all cycles of Ra-223, and we believe that a patient will achieve maximal benefit by completing all cycles of therapy.
Conclusion
Ra-223 is effective and tolerable for bone metastases in patients with CRPC. Data from post hoc safety analyses and large early clinical experiences indicate a more favorable safety profile when Ra-223 is used early in metastatic disease. When detected early in treatment, the impact of hematologic and other AEs can be minimized with appropriate precautions.
